Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half

Thu, 13 Aug 2026 12:07:00 -0400

Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission.

Inline Viewer: ADIA NUTRITION, INC. 10-Q 2026-06-30

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/309500_adiaimage.jpg

Second Quarter 2026 Highlights

Inline Viewer: ADIA NUTRITION, INC. 10-Q 2026-06-30

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/309500_adiaimage.jpg

Second Quarter 2026 Highlights

Full Sail University

To view an enhanced version of this graphic, please visit:

Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing

Tue, 11 Aug 2026 08:00:00 -0400

Winter Park, Florida--(Newsfile Corp. - August 11, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced a new educational partnership with Full Sail University. As part of the collaboration, Adia Med Chief Executive Officer Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026, at 1:00 p.m. to both in-person students and those joining live online.

Full Sail University

To view an enhanced version of this graphic, please visit:

Adia Med to Host Dinner for Physicians at Christner's Steakhouse on August 5 to Discuss Clinical Studies and Collaboration Opportunities

Wed, 05 Aug 2026 16:30:00 -0400

Winter Park, Florida--(Newsfile Corp. - August 5, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced that it will host a private dinner for physicians and investors on Wednesday, August 5, 2026, at 7:00 PM at Christner's Steakhouse.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/308113_adia_med_x_banner.jpg

The dinner will provide an overview of Adia Med's current clinical studies, including its ongoing Autism Spectrum Disorder research study and other regenerative medicine initiatives. Attending

Adia Med to Host Dinner for Physicians at Christner's Steakhouse on August 5 to Discuss Clinical Studies and Collaboration Opportunities

Wed, 05 Aug 2026 16:30:00 -0400

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/308113_adia_med_x_banner.jpg

The dinner will provide an overview of Adia Med's current clinical studies, including its ongoing Autism Spectrum Disorder research study and other regenerative medicine initiatives. Attending

Adia Med completes Phase 1, launches Phase 2 of ASD study

Wed, 29 Jul 2026 06:02:09 -0400

Adia Med Inc. (OTCQB: ADIA) announced the completion of Phase 1 treatment for the first cohort of its Autism Spectrum Disorder clinical study and the formal launch of Phase 2, according to a company statement.

The first cohort of 30 children, ages 3 to 12 with confirmed ASD diagnoses, began Phase 1 treatment on May 1, 2026. Following approval from the Institutional Review Board, the company reduced Phase 1 by one month, allowing the cohort to complete the phase ahead of the original schedule.

The study, listed on ClinicalTrials.gov under identifier NCT07304440, evaluates the safety and preliminary effectiveness of AdiaVita — a

Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study

Wed, 29 Jul 2026 06:00:00 -0400

Next Cohort of 30 Children to Begin a New Phase 1 Treatment Group on October 1, 2026, as Successive Enrollment Continues Every Three Months

Winter Park, Florida--(Newsfile Corp. - July 29, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced two distinct milestones in its Autism Spectrum Disorder (ASD) clinical research study (ClinicalTrials.gov Identifier: NCT07304440): the completion of Phase 1 treatment for the study's first cohort of children, and the formal launch of Phase 2 of the study. Separately, the company confirmed that a new cohort of 30 children will begin its own Phase 1 treatment on October 1, 2026, as

Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study

Wed, 29 Jul 2026 06:00:00 -0400

Next Cohort of 30 Children to Begin a New Phase 1 Treatment Group on October 1, 2026, as Successive Enrollment Continues Every Three Months

Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website

Wed, 15 Jul 2026 09:30:00 -0400

New Platform Now Live, Featuring Expanded Sections on Clinical Studies, Stem Cell Therapies, Aesthetics, Media, Podcasts, Case Studies, and Investor Resources

Winter Park, Florida--(Newsfile Corp. - July 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a clinical-stage regenerative medicine company, today announced the launch of its redesigned corporate website. The redesigned website is now live, with the project still in progress and active changes and improvements currently being made.

Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website

To view an enhanced version of

Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website

Wed, 15 Jul 2026 09:30:00 -0400

New Platform Now Live, Featuring Expanded Sections on Clinical Studies, Stem Cell Therapies, Aesthetics, Media, Podcasts, Case Studies, and Investor Resources

Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website

To view an enhanced version of

Adia Med's Rise, Highlighting 2.5 Years of Growth Toward NASDAQ

Mon, 13 Jul 2026 09:00:00 -0400

Winter Park, Florida--(Newsfile Corp. - July 13, 2026) - Adia Med Inc. (OTCQB: ADIA) (formerly Adia Nutrition Inc.), focused on regenerative medicine, stem cell therapies, and biologics, today highlighted its rapid advancement and major milestones achieved since the January 2024 leadership transition.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/304722_adia_med_x_banner.jpg

On January 22, 2024, Larry Powalisz assumed the role of CEO and Director following a change of control, with Rebecca Miller appointed as CFO. Since the transition, Adia Med Inc. has been bootstrap

Adia Med's Rise, Highlighting 2.5 Years of Growth Toward NASDAQ

Mon, 13 Jul 2026 09:00:00 -0400

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/304722_adia_med_x_banner.jpg

On January 22, 2024, Larry Powalisz assumed the role of CEO and Director following a change of control, with Rebecca Miller appointed as CFO. Since the transition, Adia Med Inc. has been bootstrap

Adia Nutrition changes its name to Adia Med Inc. on OTC Markets

Thu, 09 Jul 2026 08:04:02 -0400

Adia Nutrition, Inc. (OTCQB: ADIA) announced that FINRA has processed its corporate name change to Adia Med Inc., with the update reflected on the FINRA Daily List on July 9, 2026. Trading under the new name was expected to begin July 10, 2026, on the OTC Markets.

The company received confirmation of the name change from its transfer agent, Colonial Stock Transfer Company, Inc., following FINRA's review of the corporate action.

"This name change to Adia Med Inc. better reflects who we are today and where we're headed," said Larry Powalisz, CEO of Adia Med Inc. "As we continue advancing innovative stem

Adia Nutrition to Trade as Adia Med Inc. After Lightning-Fast FINRA Review

Thu, 09 Jul 2026 08:00:00 -0400

Name change to appear on Daily List today following expedited review; trading begins tomorrow

Winter Park, Florida--(Newsfile Corp. - July 9, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA) announced today that FINRA has processed its corporate name change to Adia Med Inc. on an expedited timeline. The name change will be reflected on the FINRA Daily List today, with trading under the new name expected to begin tomorrow, Friday, July 10, 2026, on the OTC Markets.

To view an enhanced version of this graphic, please visit:

Adia Nutrition to Trade as Adia Med Inc. After Lightning-Fast FINRA Review

Thu, 09 Jul 2026 08:00:00 -0400

Name change to appear on Daily List today following expedited review; trading begins tomorrow

To view an enhanced version of this graphic, please visit:

Adia Nutrition seeks FINRA approval for name change to Adia Med

Tue, 07 Jul 2026 10:21:09 -0400

Adia Nutrition Inc. (OTCQB: ADIA) announced it has reached the final stage of its corporate name change application to Adia Med Inc., according to a press release issued July 7, 2026.

The company stated that after several months of review by the Financial Industry Regulatory Authority (FINRA), which included three rounds of comments and the submission of supporting documentation, it believes all outstanding requirements have been met. The company anticipates FINRA approval within the coming weeks.

"We are pleased with the progress achieved through our ongoing dialogue with FINRA," said CEO Larry Powalisz. "We believe we have addressed all outstanding items and

Adia Nutrition Inc. Enters FINRA Home Stretch for Corporate Name Change to Adia Med Inc.

Tue, 07 Jul 2026 10:19:00 -0400

Company Believes All Requirements Satisfied; Approval Expected in the Coming Weeks

Winter Park, Florida--(Newsfile Corp. - July 7, 2026) - Adia Nutrition Inc. (OTCQB: ADIA) today announced it has entered the final stage of its corporate name change application from Adia Nutrition Inc. to Adia Med Inc. After several months of review by the Financial Industry Regulatory Authority (FINRA), including three rounds of comments and the submission of detailed supporting documentation, the Company believes it has now met all outstanding requirements. FINRA approval is anticipated within the coming weeks.

Adia Nutrition Inc. Enters FINRA Home Stretch for Corporate Name Change to Adia Med Inc.

Tue, 07 Jul 2026 10:19:00 -0400

Company Believes All Requirements Satisfied; Approval Expected in the Coming Weeks

Adia Med Finds Another Unicorn

Tue, 30 Jun 2026 12:49:00 -0400

CEO Larry Powalisz Spotlights Dr. Lyday, a Leading Stem Cell Champion, in New Podcast.

Winter Park, Florida--(Newsfile Corp. - June 30, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine and stem cell therapies company, today announced that CEO Larry Powalisz recently sat down for a podcast interview with Dr. Lyday, a physician recognized as a champion for stem cell-based treatments.

Dr. Lyday and CEO Larry Powalisz Podcast

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/303481_adia.jpg

During the conversation, Powalisz affectionately referred

Adia Med Finds Another Unicorn

Tue, 30 Jun 2026 12:49:00 -0400

CEO Larry Powalisz Spotlights Dr. Lyday, a Leading Stem Cell Champion, in New Podcast.

Dr. Lyday and CEO Larry Powalisz Podcast

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/303481_adia.jpg

During the conversation, Powalisz affectionately referred

Adia Med Improves Quality of Care with Advanced Ultrasound-Guided IV Training

Tue, 16 Jun 2026 10:55:00 -0400

Dr. Brian Browning to train APRNs and RNs on Butterfly portable ultrasound for more precise, comfortable, and reliable IV therapies

Winter Park, Florida--(Newsfile Corp. - June 16, 2026) - Adia Med, the regenerative medicine and advanced IV therapy division of Adia Nutrition Inc. (OTCQB: ADIA), today announced a major step forward in patient care quality. Renowned physician Dr. Brian Browning, DO, Lead Physician at Adia Med, will personally train the company's Advanced Practice Registered Nurses (APRNs) and Registered Nurses (RNs) in ultrasound-guided intravenous (IV) insertions and administrations using the innovative Butterfly portable ultrasound device.

StreetInsider.com News Articles

Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half

Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing

Adia Med to Host Dinner for Physicians at Christner's Steakhouse on August 5 to Discuss Clinical Studies and Collaboration Opportunities

Adia Med to Host Dinner for Physicians at Christner's Steakhouse on August 5 to Discuss Clinical Studies and Collaboration Opportunities

Adia Med completes Phase 1, launches Phase 2 of ASD study

Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study

Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study

Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website

Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website

Adia Med's Rise, Highlighting 2.5 Years of Growth Toward NASDAQ

Adia Med's Rise, Highlighting 2.5 Years of Growth Toward NASDAQ

Adia Nutrition changes its name to Adia Med Inc. on OTC Markets

Adia Nutrition to Trade as Adia Med Inc. After Lightning-Fast FINRA Review

Adia Nutrition to Trade as Adia Med Inc. After Lightning-Fast FINRA Review

Adia Nutrition seeks FINRA approval for name change to Adia Med

Adia Nutrition Inc. Enters FINRA Home Stretch for Corporate Name Change to Adia Med Inc.

Adia Nutrition Inc. Enters FINRA Home Stretch for Corporate Name Change to Adia Med Inc.

Adia Med Finds Another Unicorn

Adia Med Finds Another Unicorn

Adia Med Improves Quality of Care with Advanced Ultrasound-Guided IV Training